Subscribe To
NVO / Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says
![Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says](https://cdn.snapi.dev/images/v1/m/9/107310826-1696353063640-gettyimages-1692436765-64393-48-ms-1928-2135998.jpeg)
NVO News
![Why Novo Nordisk Stock Flopped on Friday Why Novo Nordisk Stock Flopped on Friday](https://cdn.snapi.dev/images/v1/w/0/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f7537592ftwo-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscopejpgopresizew400h400-2140089.jpg)
By The Motley Fool
November 3, 2023
Why Novo Nordisk Stock Flopped on Friday
An analyst's price target bump was overshadowed by an insider's stock sale. Both were relatively small-scale events. more_horizontal
![Novo Nordisk to release clinical update on star drug Wegovy Novo Nordisk to release clinical update on star drug Wegovy](https://cdn.snapi.dev/images/v1/g/c/shutterstock-2338223569-65451876ea5af-2139420.jpg)
By Proactive Investors
November 3, 2023
Novo Nordisk to release clinical update on star drug Wegovy
Novo Nordisk (NYSE:NVO) remains firmly in favour with analysts at Barclays ahead of the latest trial data for diabetes drug Wegovy that is due next we more_horizontal
![Weight loss drug Wegovy sales fuel Novo Nordisk stock performance Weight loss drug Wegovy sales fuel Novo Nordisk stock performance](https://cdn.snapi.dev/images/v1/a/6/weight-loss-drug-wegovy-sales-fuel-novo-nordisk-stock-performance-2137363.jpg)
By Yahoo Finance
November 2, 2023
Weight loss drug Wegovy sales fuel Novo Nordisk stock performance
Novo Nordisk (NVO) stock rose after the pharmaceutical company reported strong third-quarter sales growth, fueled by its popular weight-loss drug, Weg more_horizontal
![Novo Nordisk: 80% of U.S. Wegovy patients with insurance paying less than $25/month Novo Nordisk: 80% of U.S. Wegovy patients with insurance paying less than $25/month](https://cdn.snapi.dev/images/v1/y/l/r6v5qg6h4flfvez56lmufegp6m-2136441.jpg)
By Reuters
November 2, 2023
Novo Nordisk: 80% of U.S. Wegovy patients with insurance paying less than $25/month
The majority of U.S. patients with health insurance coverage taking Novo Nordisk's powerful weight-loss drug Wegovy are paying less than $25 per month more_horizontal
![US Wegovy Supply to Expand ‘Gradually': Novo Nordisk CEO US Wegovy Supply to Expand ‘Gradually': Novo Nordisk CEO](https://cdn.snapi.dev/images/v1/k/4/us-wegovy-supply-to-expand-gradually-novo-nordisk-ceo-2136421.jpg)
By Bloomberg Markets and Finance
November 2, 2023
US Wegovy Supply to Expand ‘Gradually': Novo Nordisk CEO
Novo Nordisk CEO Lars Fruergaard Jorgensen says starter doses of the company's weight loss medications will “be lowered somewhat” through the end more_horizontal
![Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says](https://cdn.snapi.dev/images/v1/m/9/107310826-1696353063640-gettyimages-1692436765-64393-48-ms-1928-2135998.jpeg)
By CNBC
November 2, 2023
Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says
Novo Nordisk said its blockbuster weight-loss drug Wegovy could receive expanded approval from the U.S. Food and Drug Administration within six months more_horizontal
![Novo Nordisk adding in-house fill-finish capacity for Wegovy's European pen, Ozempic Novo Nordisk adding in-house fill-finish capacity for Wegovy's European pen, Ozempic](https://cdn.snapi.dev/images/v1/3/i/l6u7quzijbn5lihsxvjm7cf56i-2135949.jpg)
By Reuters
November 2, 2023
Novo Nordisk adding in-house fill-finish capacity for Wegovy's European pen, Ozempic
Novo Nordisk is ramping up its in-house manufacturing capacity to fill injection pens for its diabetes drug Ozempic and for the European version of it more_horizontal
![Novo Nordisk: obesity drugs priority over century-old focus on insulin Novo Nordisk: obesity drugs priority over century-old focus on insulin](https://cdn.snapi.dev/images/v1/u/x/n75js65erzmdbn5th2chafttie-2135422.jpg)
By Reuters
November 2, 2023
Novo Nordisk: obesity drugs priority over century-old focus on insulin
Novo Nordisk said on Thursday treating obesity with its weight-loss drug Wegovy as a precursor to type 2 diabetes was a priority for the company, cont more_horizontal